What drugs target Complement C5?

9+ drugs target Complement C5, including Ultomiris, Izervay, Avacincaptad, Veopoz, AVACINCAPTAD PEGOL SODIUM.

What drug classes act on Complement C5?

Drug classes acting on Complement C5 include Complement Inhibitor [EPC], Complement Inhibitors, Complement C5 inhibitor.

9 drugs 8 marketed 1 in Phase 3

All drugs that target Complement C5 — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Ultomiris · AstraZeneca · Complement Inhibitor [EPC] · Cardiovascular
Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells.
Izervay · Astellas Pharma · Immunology
Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response.
Avacincaptad · Aviceda Therapeutics, Inc. · Ophthalmology
Veopoz · Regeneron · Complement Inhibitor [EPC] · Immunology
Veopoz works by blocking the activity of Complement C5, a protein that contributes to inflammation.
AVACINCAPTAD PEGOL SODIUM · Complement Inhibitors · Immunology
ULTOMIRIS · ALEXION PHARM · Other
Ultomiris · Alexion Pharmaceuticals, Inc. · Other
Soliris · Apellis Pharmaceuticals, Inc. · Neuroscience

BOL-303259-X · Bausch & Lomb Incorporated · Complement C5 inhibitor · Ophthalmology
BOL-303259-X is a small molecule that inhibits the complement C5 pathway to reduce inflammation and tissue damage in the eye.